5 Turnaround Stocks Getting Some Traction on Wall Street
Analysts, investors and Wall Street gurus seem to think the worst is over and companies that were beat up initially may be in a sweet position down the line. Here are five companies that…
All Work
Chris Lange
Snowflake Enters the Market With a Bang
Shares of data warehousing cloud service provider Snowflake entered the market with a bang on Wednesday.
What Analysts Are Saying About FedEx After Earnings
Analysts cheered the FedEx first-quarter fiscal 2021 financial results report, as many are chasing it higher with their target hikes.
Why This Interim Liver Study Is Huge for Arrowhead Pharma
Arrowhead Pharmaceuticals has announced positive interim 24-week liver biopsy results in four subjects from its midstage study of ARO-AAT. Shares rallied on the news early Wednesday.
What’s Going on in Adobe’s Record Quarter
Adobe reported fiscal third-quarter earnings after markets closed Tuesday and posted $2.57 in earnings per share (EPS) and a record $3.23 billion in revenue, both better than analysts' expectations.
Why FedEx’s Q1 Is So Impressive
FedEx reported fiscal first-quarter 2021 financial results after markets closed Tuesday. The company crushed both top- and bottom-line estimates.
Why This Epilepsy Study Is Huge for Marinus Pharmaceuticals
The announcement of positive topline results in a late-stage epilepsy trial prompted a rally in Marinus Pharmaceuticals shares on Tuesday.
Laird Superfood Announces Potential Pricing for IPO
Laird Superfood intends to price more than 2 million shares for an initial public offering valued up to over $50 million.
Why This FDA Win for Ardelyx Is Definitely a ‘Sell the News’ Moment
Companies winning approval from the FDA or beating a trial are expected in some cases. If investors already have priced this news into the stock, when it actually comes around they tend to sell…
How Cassava Sciences Could Be Pioneering a Groundbreaking Alzheimer’s Treatment
Cassava Sciences reported good results from a mid-stage study of its sumifilam treatment for Alzheimer's disease. Shares soared on the news.
Is the Turnaround at GameStop Sustainable After 2020?
Has video game retailer GameStop broken out of the downward spiral that had captured it for so long? Two analysts are optimistic about the company's near-term outlook.
Caledonia Rolls the Dice on Scientific Games With Massive Stake
Scientific Games was one of Monday’s big winners after the company announced that it had reached an agreement with a credentialed gaming industry investor to buy a significant stake in the company.
Corsair Gaming Announces Potential Pricing for IPO
High-performance gear provider Corsair Gaming intends to price 14 million shares to result in an initial public offering valued up to nearly $290 million.
Are Immunomedics Shareholders Getting Enough in the Acquisition?
Immunomedics shares more than doubled on Monday after the firm announced that it would be acquired by Gilead Sciences in one of the biggest deals to go down in the health care sector this…
What Analysts Are Saying About Lululemon After Earnings
Though Lululemon Athletica topped estimates when it posted its fiscal second-quarter results this week, investors ultimately sent shares lower. Yet, analysts remain fairly positive on the stock.
Short Sellers Hike Their Bets in Major Biotechs
The August 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Short Sellers Yield on Semiconductors, With One Major Exception
The August 31 short interest data have been compared with the previous report, and short sellers backed off from most of these selected semiconductor stocks, with one major exception.
Peloton Races Ahead With Q4 Results
Peloton Interactive Inc. (NASDAQ: PTON) released its fiscal fourth-quarter earnings report before the opening bell Tuesday. The firm said that it had $0.27 in earnings per share (EPS) and $607.1 million in revenue, which…
Oracle Rides to More Multiyear Highs After Q1 Results
Oracle reported fiscal first-quarter earnings per share of $0.93 and $9.37 billion in revenue after markets closed Thursday. Results beat both top- and bottom-line estimates.
Bed Bath & Beyond Added to Best Ideas List and Could Be Turning Around Soon
Bed Bath & Beyond stock has been beaten up so far this year, but one analyst thinks that it has the potential to rally.